Overview

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

Status:
Not yet recruiting

Trial end date:
2025-08-30

Target enrollment:

Participant gender:

Summary

To assess the outcomes of NRM when administering pharmacologic pretransplant immunosuppression (PTIS) followed by pretransplant reduced toxicity conditioning (RTC) and an allogeneic stem cell transplant (allo-SCT) and post-transplant graft-versus-host disease prophylaxis based on post-transplant cyclophosphamide (PT-Cy) in patients with inherited blood disorders.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Bortezomib
Busulfan
Cyclophosphamide
Cyclosporine
Cyclosporins
Dexamethasone
Fludarabine
Mycophenolic Acid
Rituximab
Tacrolimus
Thymoglobulin